Utama › Limfoma Burkitt › Hawaii
Kajian klinikal Limfoma Burkitt di Hawaii
5 kajian untuk Limfoma Burkitt sedang mencari peserta di lokasi di Hawaii.
Bandar di Hawaii
Teks kajian rasmi (Bahasa Inggeris)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Kapiolani Medical Center for Women and Children, Honolulu
Mengambil pesertaFasa 2
366 Days – 46 Years · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Straub Clinic and Hospital, Honolulu
- Kapiolani Medical Center for Women and Children, Honolulu
- Pali Momi Medical Center, ‘Aiea
Mengambil pesertaFasa 3
Umur 18 hingga 39 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT03150693Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Kapiolani Medical Center for Women and Children, Honolulu
Mengambil pesertaFasa 2
365 Days · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Kapiolani Medical Center for Women and Children, Honolulu
Mengambil pesertaFasa 2
Umur 1 hingga 30 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Kapiolani Medical Center for Women and Children, Honolulu
Mengambil pesertaFasa 3
365 Days – 25 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03959085Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.